Purpose

This randomized, double-blind controlled trial investigates whether intraoperative IV methadone (0.15 mg/kg based on ideal body weight) reduces acute postoperative pain and opioid consumption in patients undergoing elective total knee arthroplasty under spinal anesthesia with mepivacaine.

Condition

Eligibility

Eligible Ages
Between 18 Years and 75 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Criteria

Inclusion

- Ages 18-75 years of age

- Undergoing elective primary total knee arthroplasty with mepivacaine in the spinal
anesthesia

Exclusion

- Allergy to methadone or mepivacaine

- Severe liver disease defined as Child's Pugh Class C

- End stage renal disease requiring dialysis

- Known diagnosis of prolonged QT syndrome

- Currently pregnant

- Unable to provide written, informed consent

- Non-English speaking

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Double (Participant, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
Methadone
Patients will intraoperatively receive methadone 0.15mg/kg IV, based on ideal body weight.
  • Drug: Methadone Hydrochloride
    Patients will intraoperatively be administered methadone 0.15mg/kg IV, based on ideal body weight.
No Intervention
No Methadone
Patients will NOT receive methadone.

Recruiting Locations

Medical University of South Carolina
Charleston 4574324, South Carolina 4597040 29425
Contact:
Haley Nitchie, MHA
843-792-1869
nitchie@musc.edu

More Details

NCT ID
NCT07226076
Status
Recruiting
Sponsor
Medical University of South Carolina

Study Contact

Haley Nitchie, MHA
843-792-1869
nitchie@musc.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.